

# American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

## Eligibility

### Inclusion Criterion

- postmenopausal women with hormone receptor–positive breast cancer

### Exclusion Criterion

## Decision Variables

postmenopausal

Rec\_1: Cond\_15: DV\_31

Rec\_1: Cond\_14: DV\_30

Rec\_7: Cond\_13: DV\_27

adjuvant treatment

Rec\_1: Cond\_15: DV\_40

Rec\_1: Cond\_14: DV\_38

tamoxifen use

Rec\_1: Cond\_15: DV\_41

Rec\_1: Cond\_14: DV\_39

Rec\_4: Cond\_9: DV\_35

AI

Rec\_4: Cond\_7: DV\_8

tamoxifen

Rec\_4: Cond\_7: DV\_37

in the primary setting

Rec\_4: Cond\_9: DV\_13

in the extended adjuvant setting

Rec\_4: Cond\_9: DV\_14

in a AI clinical trial

Rec\_4: Cond\_9: DV\_15

AI use

Rec\_4: Cond\_9: DV\_34

not menopausal

Rec\_1: Cond\_1: DV\_1

treatment-induced amenorrhea

Rec\_1: Cond\_1: DV\_24

adverse effects are intolerable

Rec\_6: Cond\_12: DV\_25

persistently noncompliant with therapy

Rec\_6: Cond\_12: DV\_26

recommending adjuvant endocrine therapy

Rec\_6: Cond\_16: DV\_32

Recommending adjuvant endocrine therapy

Rec\_6: Cond\_17: DV\_33

intolerant of one AI

Rec\_7: Cond\_13: DV\_29

still candidate for adjuvant endocrine therapy

Rec\_7: Cond\_13: DV\_28